DBV Technologies (NASDAQ:DBVT) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of DBV Technologies (NASDAQ:DBVT) in a report released on Sunday. The brokerage issued a hold rating on the stock.

Separately, JMP Securities reaffirmed a “market outperform” rating and set a $10.00 price objective on shares of DBV Technologies in a report on Friday, January 10th.

DBV Technologies Trading Down 5.3 %

Shares of NASDAQ DBVT opened at $6.46 on Friday. DBV Technologies has a one year low of $2.20 and a one year high of $8.32. The business has a fifty day simple moving average of $4.53 and a 200 day simple moving average of $3.89. The firm has a market capitalization of $132.88 million, a price-to-earnings ratio of -1.44 and a beta of 0.71.

Institutional Investors Weigh In On DBV Technologies

An institutional investor recently bought a new position in DBV Technologies stock. Boxer Capital Management LLC purchased a new stake in DBV Technologies S.A. (NASDAQ:DBVT) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 50,000 shares of the company’s stock, valued at approximately $154,000. Boxer Capital Management LLC owned 0.24% of DBV Technologies at the end of the most recent reporting period. Institutional investors own 71.74% of the company’s stock.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.